Oxford Immunotec Global (OXFD) Given a $21.00 Price Target at BTIG Research

BTIG Research set a $21.00 target price on Oxford Immunotec Global (NASDAQ:OXFD) in a research report released on Monday, December 18th. The brokerage currently has a buy rating on the stock.

A number of other research firms also recently issued reports on OXFD. BidaskClub downgraded shares of Oxford Immunotec Global from a hold rating to a sell rating in a research note on Saturday, December 9th. Zacks Investment Research raised shares of Oxford Immunotec Global from a sell rating to a hold rating in a research note on Wednesday, October 4th. Cowen reiterated a buy rating and set a $19.00 price target on shares of Oxford Immunotec Global in a report on Thursday, September 28th. ValuEngine cut shares of Oxford Immunotec Global from a hold rating to a sell rating in a report on Tuesday, October 31st. Finally, Robert W. Baird reiterated a buy rating and set a $20.00 price target on shares of Oxford Immunotec Global in a report on Wednesday, November 1st. Three analysts have rated the stock with a sell rating and four have given a buy rating to the company. Oxford Immunotec Global currently has a consensus rating of Hold and an average price target of $19.75.

Shares of Oxford Immunotec Global (OXFD) traded up $0.21 during trading hours on Monday, hitting $12.19. 286,083 shares of the stock traded hands, compared to its average volume of 234,498. Oxford Immunotec Global has a 52-week low of $10.81 and a 52-week high of $19.51. The company has a market capitalization of $307.35, a P/E ratio of -6.03 and a beta of -0.09. The company has a current ratio of 4.72, a quick ratio of 4.30 and a debt-to-equity ratio of 0.38.

In other news, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $13.35, for a total transaction of $40,050.00. Following the transaction, the director now owns 17,778 shares in the company, valued at approximately $237,336.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 8.11% of the company’s stock.

Several hedge funds have recently made changes to their positions in OXFD. Voya Investment Management LLC raised its position in shares of Oxford Immunotec Global by 16.0% during the 2nd quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock valued at $224,000 after purchasing an additional 1,845 shares during the period. Alliancebernstein L.P. bought a new stake in Oxford Immunotec Global in the 2nd quarter valued at $247,000. Asymmetry Capital Management L.P. bought a new stake in Oxford Immunotec Global in the 2nd quarter valued at $273,000. The Manufacturers Life Insurance Company increased its holdings in Oxford Immunotec Global by 8.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,631 shares of the company’s stock valued at $313,000 after acquiring an additional 1,500 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in Oxford Immunotec Global by 9.1% in the 2nd quarter. Rhumbline Advisers now owns 24,500 shares of the company’s stock valued at $412,000 after acquiring an additional 2,053 shares during the last quarter. Hedge funds and other institutional investors own 89.35% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Oxford Immunotec Global (OXFD) Given a $21.00 Price Target at BTIG Research” was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2018/01/13/btig-research-analysts-give-oxford-immunotec-global-oxfd-a-21-00-price-target-updated-updated.html.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply